Langue

Certains contenus peuvent être disponibles uniquement en anglais.

Recommendations for the use of slow-release oral morphine as opioid agonist therapy

Evidence, Guidelines and Recommendations

Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).

Détails

Catégorie
Evidence, Guidelines and Recommendations
Format
Document PDF
Taille du fichier
Fichier introuvable.
Téléchargements
23
Ajouté
25 août 2025
Tags
Psychiatrie
Douleur
Santé mentale
Troubles liés à l'usage de substances
Soins primaires
Médecine interne
Médecine d’urgence

Ressources connexes

BC’s Guideline for the Clinical Management of Opioid Addiction (2017)
Amidst a provincial overdose crisis, British Columbia made concerted efforts to address gaps in the provision of evidence-based treatment options and care for individuals with opioid use disorder, including the development of provincial guidelines as well as the creation of its aligned training program, the Provincial Opioid Addiction Treatment Support Program.